Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.

We developed a nanocarrier system of herceptin-conjugated nanoparticles of d-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate (TPGS)-cisplatin prodrug (HTCP NPs) for targeted co-delivery of cisplatin, docetaxel and herceptin for multimodality treatment of breast cancer of high human epidermal growth factor receptor 2 (HER2) overexpression. Co-polymers poly(lactic acid)-TPGS (PLA-TPGS) and carboxyl group-terminated TPGS (TPGS-COOH) were also added in the polymeric matrix to stabilize the prodrug nanoparticles and to facilitate herceptin conjugation. The HTCP NPs of high, moderate and low docetaxel versus cisplatin ratio were prepared by the nanoprecipitation method, which showed a pH-sensitive release for both anticancer drugs. The therapeutic effects of HTCP NPs were evaluated in vitro and compared with Taxotere® and cisplatin. The HTCP NPs of high docetaxel versus cisplatin ratio were found to have better efficacy than those of moderate and low docetaxel versus cisplatin ratio. The targeting effects of the HTCP NPs were demonstrated by a much lower IC50 value of 0.0201+0.00780+0.1629μg/mL of docetaxel+cisplatin+herceptin for SK-BR-3 cells, which are of high HER2 overexpression, than that of 0.225+0.0875+1.827μg/mL for NIH3T3 cells, which are of low HER2 overexpression, after 24h incubation. The same design of TPGS prodrug nanoparticles can also be applied for targeted co-delivery of other hydrophilic and hydrophobic drugs.

[1]  Si-Shen Feng,et al.  Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. , 2012, Biomaterials.

[2]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[3]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[4]  S. Feng,et al.  Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. , 2008, Biomaterials.

[5]  J. Graham,et al.  Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[7]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[8]  C. Sakakura,et al.  Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[9]  S. Feng,et al.  Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. , 2012, Biomaterials.

[10]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[11]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[12]  Kai-Hsiang Chuang,et al.  Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. , 2010, Biomaterials.

[13]  S. Feng,et al.  Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. , 2012, International journal of pharmaceutics.

[14]  Kai Li,et al.  Herceptin functionalized polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide nanoparticles for tumor cell sorting and detection. , 2011, Biomaterials.

[15]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for new-concept chemotherapy , 2004, Expert review of medical devices.

[16]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Si-Shen Feng,et al.  Vitamin E TPGS as a molecular biomaterial for drug delivery. , 2012, Biomaterials.

[18]  Shu Chien,et al.  Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , 2003 .

[19]  Dar-Ren Chen,et al.  A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers , 2012, Cancer Chemotherapy and Pharmacology.

[20]  Si-Shen Feng,et al.  Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. , 2006, Biomaterials.

[21]  Leone Spiccia,et al.  Nanomaterials: Applications in Cancer Imaging and Therapy , 2011, Advanced materials.

[22]  D. Slamon,et al.  Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Si-Shen Feng,et al.  Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. , 2011, Biomaterials.

[24]  Si-Shen Feng,et al.  The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. , 2006, Biomaterials.

[25]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[26]  J. Kern,et al.  HER2-targeted gene transfer. , 1997, Human gene therapy.

[27]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[28]  Jun Ding,et al.  Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. , 2012, Biomaterials.